Compare SUPX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPX | CGEN |
|---|---|---|
| Founded | 2021 | 1993 |
| Country | Singapore | Israel |
| Employees | 40 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.4M | 270.4M |
| IPO Year | N/A | 2001 |
| Metric | SUPX | CGEN |
|---|---|---|
| Price | $8.06 | $2.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 374.3K | ★ 541.7K |
| Earning Date | 05-14-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.61 | $1.29 |
| 52 Week High | $76.00 | $3.24 |
| Indicator | SUPX | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 59.63 |
| Support Level | $6.76 | $1.45 |
| Resistance Level | $11.42 | $3.24 |
| Average True Range (ATR) | 1.10 | 0.17 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 23.23 | 48.58 |
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.